Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD

Схожие документы

• Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
  по: Karabis, Andreas, et al.
  Опубликовано: (2014)
• Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
  по: McGarvey, Lorcan, et al.
  Опубликовано: (2016)
• Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
  по: Ulrik, Charlotte Suppli
  Опубликовано: (2012)
• Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
  по: Ramos, Mafalda, et al.
  Опубликовано: (2016)
• Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study
  по: Wise, Robert A., et al.
  Опубликовано: (2018)